Fed Week Chaos: 3 LEAPS Setups Hiding in Plain Sight

Most traders are staring at their P&L right now, watching oil rip past $90 and 10-year yields flirt with levels not seen since 2007, convinced this is a sell-everything moment. They're probably wrong — or at least, they're asking the wrong question. The smarter question isn't will the Fed hike? It's what happens to volatility pricing the moment the uncertainty resolves? Because right now, the market is paying a premium for fear, and that fear is compressing into specific names — Apple (AAPL) and Moderna (MRNA) chief among them — in ways that create asymmetric LEAPS setups that most retail traders walk right past. The macro noise is deafening. That's usually when the signal gets interesting.

What's Actually Happening

Strip away the headlines and you've got a fairly coherent story: the Fed is almost certainly pausing rate hikes at this week's FOMC meeting, but they're not done talking hawkishly. Chair Powell will use the press conference to keep hike optionality alive for November, which means bond markets stay jittery and equities stay choppy — but not necessarily broken.

The real pressure is coming from two structural forces. First, crude oil (WTI) has run from the low $70s in June to above $90, acting as a de facto tax on consumer spending and complicating the Fed's inflation calculus. Second, the 10-year Treasury yield is pushing levels that make equity valuations genuinely uncomfortable — particularly for growth names whose future cash flows look less attractive when discounted at 4.5%+.

Here's the contrarian piece: Friday's bounce wasn't noise. It was the market beginning to price in a scenario where the Fed signals a higher-for-longer hold — not additional hikes — which is actually the least bad outcome equities can hope for right now. When the Fed stops tightening, the first trade is relief in rate-sensitive growth names. Apple (AAPL), despite being treated like a bond proxy lately, has the balance sheet and earnings power to re-rate sharply when the rate narrative shifts. Moderna (MRNA), sitting well off its highs with a pipeline that the market has completely written off, is a different kind of setup — binary and volatile, but potentially explosive.

Why Options Traders Should Pay Attention

Fed weeks are IV expansion events, full stop. Implied volatility across major indices and large-cap names inflates in the days leading up to the decision, peaks around the announcement, and — in the majority of historical cases — collapses sharply afterward regardless of the actual outcome. This phenomenon, known as the volatility crush, is both a trap and an opportunity depending on how you're positioned.

If you're buying short-dated options into the Fed decision, you're fighting the crush. A $0.50 call that looks cheap can become a $0.20 call within 24 hours of the announcement even if the stock moves in your direction — because the IV component of that premium evaporates. This is why most retail options traders lose money around macro events: they understand direction but not volatility dynamics.

LEAPS operate differently. Because they have 12–24 months of time value baked in, a single-week IV spike has a much smaller proportional impact on their pricing. More importantly, deep OTM LEAPS in the $0.01–$0.08 range are priced almost entirely on probability of touch and time value, not near-term IV. That means the Fed-driven volatility spike can actually make these contracts cheaper in relative terms as market makers focus their hedging on near-dated paper.

Right now, the setup in AAPL and MRNA is worth examining closely. AAPL has well-defined technical support and an earnings catalyst in late October. MRNA has pipeline data events and short interest that could fuel violent short-covering. Both names are seeing elevated near-term IV — which means far-dated, deep OTM calls are getting relatively less attention from institutional desks, creating windows where premium is thin and leverage is high.

The LEAPS Angle

Let's be specific. On Apple (AAPL), the stock has been rangebound roughly between $170 and $198 for the past several months. A 2025 LEAPS call with a strike in the $230–$240 range — well outside current trading territory — represents a bet on roughly a 20–25% move over the next 12–15 months. For a company with AAPL's capital return program, Services revenue growth trajectory, and potential Vision Pro catalyst, that's not a fantasy scenario. It's a reasonable bull case. These strikes, depending on the day and IV environment, can be found in the $0.03–$0.07 range. A $300 position controls 10 contracts on 1,000 shares. If AAPL runs to $235 by early 2025, that $0.05 call could be worth $5.00+. That's the math that makes LEAPS worth understanding.

On Moderna (MRNA), the risk-reward is different but equally compelling. The stock has been demolished — down over 70% from its pandemic peak — and the market is valuing its pipeline at something close to zero. Any positive data on its RSV, flu combo, or mRNA cancer vaccine programs could reprice the stock violently. A 2025 LEAPS call at a strike 40–50% above current levels is essentially a cheap ticket to binary upside. Premium on these can be laughably small.

Finding these specific contracts manually is time-consuming and easy to get wrong. This is precisely the use case for tools like the StrikeEdge scanner, which surfaces deep OTM LEAPS priced under $0.08 on large-cap names, filtering by liquidity, spread, and upcoming catalysts. Instead of scrolling through hundreds of option chains, traders use it to isolate the setups that fit specific criteria — letting the signal emerge from the noise before the move happens, not after.

The critical discipline with any LEAPS position in this range: size it as a defined-risk, asymmetric bet. You should be comfortable watching it go to zero, because sometimes it will. The edge is in the portfolio of these setups, not any single one.

Key Risks to Watch

The bull case breaks down in a few specific scenarios. First, if the Fed surprises with an actual hike — not just hawkish language — equities will take another leg down and LEAPS on any growth name will lose value quickly, even with time on your side. Second, oil above $95–$100 sustained would reignite CPI concerns and push the market toward pricing additional hikes into 2024, which is structurally bad for high-multiple tech. Third, AAPL has its own idiosyncratic risk: iPhone demand data out of China has been weak, and any guidance cut in the October earnings report could break technical support and delay any bull case by 6–12 months. On MRNA, clinical trial failures are binary events that can erase 20–30% of the stock overnight. If you're in LEAPS there, respect that reality.

• Surprise Fed hike: Low probability, high impact — would reprice equities broadly
• Oil above $95 sustained: Stagflation narrative returns, growth stocks suffer
• AAPL China demand miss: October earnings could break the setup's thesis
• MRNA trial failure: Binary clinical risk, position size accordingly
• Prolonged high-yield environment: Growth stock re-rating takes longer than LEAPS expiration

How to Position Into the Fed Decision

Don't try to trade the Wednesday announcement itself — that's a volatility game best left to market makers. Instead, use the pre-Fed IV expansion as a shopping window. Watch how AAPL and MRNA LEAPS premiums behave in the 24–48 hours after the decision. If IV collapses and the underlying holds its level, deep OTM calls will get cheaper in absolute terms. That's your entry window. Set your strike targets, set your maximum premium you're willing to pay, and wait for the dust to settle. The Fed meeting is the noise. The 12 months after it are the signal.